NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q3 2023
Institutional positions in NeuBase Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −6 vs. Q2 2023
- Shares held
- 347.0K
- −231.9K (−40.1%) vs. Q2 2023
- Total value
- $301.2K
- −$780.7K (−72.2%) vs. Q2 2023
- New holders
- 1
- 4 more added
- Sold out
- 7
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NBSE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 2 | $4.95K |
| Q1 2024 | 18 | $177.1K |
| Q4 2023 | 21 | $340.2K |
| Q3 2023 | 20 | $301.2K |
| Q2 2023 | 26 | $1.08M |
| Q1 2023 | 36 | $1.72M |
| Q4 2022 | 35 | $1.94M |
| Q3 2022 | 44 | $4.74M |
| Q2 2022 | 43 | $13.4M |
| Q1 2022 | 45 | $23.3M |
| Q4 2021 | 46 | $31.6M |
| Q3 2021 | 48 | $36.6M |
| Q2 2021 | 59 | $51.5M |
| Q1 2021 | 57 | $59.4M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding NeuBase Therapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Greenlight Capital Inc | 136,350 | $118.6K | 0.01% | 00.0% | Unchanged |
| Point72 Asset Management, L.P. | 62,500 | $54.4K | 0.00% | 00.0% | Unchanged |
| Carnegie Mellon University | 46,970 | $40.9K | 0.05% | 00.0% | Unchanged |
| Vanguard Group Inc | 18,981 | $16.5K | 0.00% | 00.0% | Unchanged |
| Kestra Advisory Services, LLC | 17,976 | $15.6K | 0.00% | −7,507−29.5% | Reduced |
| Jacob Asset Management of New York LLC | 15,655 | $13.6K | 0.02% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 15,550 | $13.5K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 15,482 | $13.5K | 0.00% | +3,786+32.4% | Added |
| Two Sigma Securities, LLC | 12,354 | $10.7K | 0.00% | +12,354 | New |
| Tower Research Capital LLC (TRC) | 2,432 | $2.12K | 0.00% | −5,383−68.9% | Reduced |
| Bank of America Corp | 804 | $698 | 0.00% | 00.0% | Unchanged |
| First Manhattan Co | 706 | $614 | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 440 | $383 | 0.00% | −24−5.2% | Reduced |
| Wells Fargo & Company | 65 | $56 | 0.00% | +3+4.8% | Added |
| Advisor Group Holdings, Inc. | 22 | $19 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 21 | $18 | 0.00% | 00.0% | Unchanged |
| Global Wealth Management Investment Advisory, Inc. | 12 | $10 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 12 | $10 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9 | $8 | 0.00% | +2+28.6% | Added |
| Royal Bank of Canada | 662 | $0 | 0.00% | +379+133.9% | Added |
| Armistice Capital, LLC | 0 | $0 | 0.00% | −166,174−100.0% | Sold out |
| Decheng Capital Management III (Cayman), LLC | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −12,601−100.0% | Sold out |
| CM Management, LLC | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −539−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | −105−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −68−100.0% | Sold out |